Multicenter clinical trial of cefetamet pivoxil vs cefixime in treatment of acute bacterial infections
- VernacularTitle:头孢他美酯与头孢克肟治疗急性细菌性感染多中心临床试验
- Author:
Jiatai LI
;
Caiyun ZHAO
;
Wenzhi HU
;
Demeng LIU
;
Junming GU
;
Li HUO
- Publication Type:Journal Article
- From:
Chinese Journal of New Drugs and Clinical Remedies
2001;20(2):87-90
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To evaluate the safety and efficacy of cefetamet pivoxil vs cefixime in the treatment of acute bacterial infections. METHODS: A multicenter randomized controlled clinical trial was conducted. Ninety-eight patients (M 43, F 55; age 40 a± s 13 a) with acute bacterial infections of cefetamet group were given cefetamet pivoxil 250-500 mg, po, bid, for 7-14 d, and ninty-five patients (M 44, F 51; age 42 a±14 a) of cefixime group were given cefixime 200 mg, po, bid, for 7-14 d. RESULTS: The overall clinical efficacy rates were 95 % and 94 %, the bacterial clearance rates were 96 % and 94 %, the bacterial sensitive rates were 98 % and 96 %, the adverse reaction rates were 7 % and 6 %, respectively. There was no statistical significance between two groups (P>0.05). CONCLUSION: Cefetamet pivoxil and cefixime are effective and safe in the treatment of acute bacterial infections.
